AI Article Synopsis
- The Omicron subvariant BA.2 has become the dominant strain, replacing BA.1 and earlier variants like Alpha, Gamma, and Delta in many countries.
- A cell culture infection assay was conducted to compare the sensitivity of BA.2 and BA.1 to five neutralizing antibodies and antiviral drugs, revealing significant differences in their effectiveness.
- Findings indicate that BA.1 and BA.2 have reduced sensitivity to certain antibodies, while other antiviral drugs showed more consistent efficacy, highlighting the importance of understanding variant characteristics for effective treatment options.
Article Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251960 | PMC |
| http://dx.doi.org/10.1016/j.antiviral.2022.105372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!